Primary Hyperoxaluria Type 1
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (11)
Total enrollment: 313 patients across 11 trials
Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.